Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
The NNT analysis demonstrates that treatment with zanubrutinib versus acalabrutinib is associated with more favorable clinical and economic outcomes in R/R CLL, especially in high-risk CLL patients.
Authors
- Constantine S. Tam
- Asher Chanan-Kahn
- Marjan Massoudi
- Rhys Williams
- Mei Xue
- Mazyar Shadman
- David Campbell
- Keri Yang
Institutions
- National University of Misiones (AR)
- University of Washington (US)
- WinnMed (US)
- Monash University (AU)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1080/14796694.2026.2615736
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00